Black Diamond Therapeutics, Inc. BDTX
We are a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of our company is built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Our MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain-penetrant to treat central nervous system (CNS) disease. Our compounds target families of oncogenic mutations in clinically validated pathways. Our lead clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). We plan to initiate a randomized Phase 2 trial of silevertinib in newly diagnosed patients with EGFR altered glioblastoma (GBM) in the second quarter of 2026.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70.0M | $0 | — | — | — | $0 | $0 | $0 | — |
| R&D | $33.6M | $51.3M | $59.4M | $64.4M | $96.8M | $48.2M | $21.8M | $7.0M | — |
| SG&A | $16.6M | $27.5M | $27.1M | $28.4M | $30.0M | $21.4M | $7.6M | $2.0M | — |
| Total operating expenses | $57.5M | $78.8M | $86.5M | $92.8M | $126.9M | $69.6M | $29.3M | $8.9M | — |
| Operating income | $12.5M | -$78.8M | -$86.5M | -$92.8M | -$126.9M | -$69.6M | -$29.3M | -$8.9M | — |
| Interest expense | — | — | — | — | $0 | $1.0K | $0 | — | — |
| Pre-tax income | $22.37B | -$69.68B | -$82.4M | -$91.2M | -$125.6M | -$67.3M | -$35.3M | -$8.9M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | $22.37B | -$69.68B | -$82.4M | -$91.2M | -$125.6M | -$67.3M | -$35.3M | -$8.9M | — |
| EPS, basic | 0.39 | -1.27 | -1.88 | -2.52 | -3.47 | -2.05 | — | — | — |
| EPS, diluted | 0.39 | -1.27 | -1.88 | -2.52 | -3.47 | -2.05 | -16.99 | -4.42 | — |
| Shares, diluted (wtd. avg.) | 57.6M | 55.0M | 44.0M | 36.3M | 36.2M | 32.9M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $21.0M | $36.4M | $57.0M | $35.5M | $67.0M | $35.8M | $154.7M | $51.7M | $7.9M |
| Short-term investments | $107.7M | $62.1M | $75.2M | $88.5M | $144.0M | $280.5M | $0 | — | — |
| Total current assets | $132.4M | $101.2M | $134.0M | $127.7M | $215.7M | $319.6M | $155.7M | $51.7M | — |
| Property, plant and equipment | $365.0K | $1.4M | $1.7M | $2.6M | $3.0M | $385.0K | $164.0K | $134.0K | — |
| Total assets | $143.0M | $122.6M | $158.6M | $156.3M | $247.7M | $329.7M | $158.3M | $51.8M | — |
| Accounts payable | $579.0K | $4.0M | $2.3M | $1.9M | $4.1M | $2.5M | $2.0M | $416.0K | — |
| Total current liabilities | $15.7M | $20.6M | $19.6M | $15.3M | $23.6M | $14.2M | $4.9M | $2.6M | — |
| Total liabilities | $30.8M | $39.4M | $41.8M | $40.6M | $51.8M | $21.9M | $4.9M | $6.6M | — |
| Retained earnings | -$464.7M | -$487.1M | -$417.4M | -$335.0M | -$243.8M | -$118.2M | -$51.0M | -$15.7M | — |
| Total equity | $112.2M | $83.3M | $116.7M | $115.7M | $195.9M | $307.8M | -$47.2M | -$15.5M | -$6.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $29.6M | -$62.3M | -$66.7M | -$85.1M | -$100.1M | -$52.1M | -$24.7M | -$8.5M | — |
| Depreciation and amortisation | $325.0K | $343.0K | $437.0K | $508.0K | $205.0K | $52.0K | $47.0K | $44.0K | — |
| Stock-based compensation | $6.6M | $10.6M | $9.6M | $12.2M | $14.0M | $7.8M | $3.6M | $64.0K | — |
| Capital expenditure | — | $0 | $33.0K | $192.0K | $2.7M | $142.0K | $21.0K | $76.0K | — |
| Investing cash flow | -$44.9M | $17.0M | $16.3M | $53.4M | $130.6M | -$281.7M | -$21.0K | -$76.0K | — |
| Financing cash flow | -$146.0K | $25.5M | $71.9M | $177.0K | $729.0K | $214.9M | $127.8M | $52.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-051474.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | — | — | — | $0 | $70.0M |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | — | -$8.9M | -$35.3M | -$67.3M | -$125.6M | -$91.2M | -$82.4M | -$69.68B | $22.37B |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Results announced Item 2.02
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |